ArticleFrontiers in cellular and infection microbiology2019
Antibacterial Activity of
Article in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Polystyrene microplastics facilitateApplied and environmental microbiology · 2026Article
- Targeting the Gut Microbiota with Herbal Compounds from Traditional Chinese Medicine: A Mechanistic Synthesis of a Novel Therapeutic Approach for Ulcerative Colitis.Journal of inflammation research · 2026Review
- Article
- Analysis of Gut Bacterial and Fungal Microbiota in Children with Autism Spectrum Disorder and Their Non-Autistic Siblings.Nutrients · 2024Article
- Potent and specific antibiotic combination therapy against Clostridioides difficile.Nature chemical biology · 2024Article
- Environmental and Nutritional Parameters Modulating Genetic Expression for Virulence Factors ofAntibiotics (Basel, Switzerland) · 2024Review
- Article
- Microbiota and functional analyses of nitrogen-fixing bacteria in root-knot nematode parasitism of plants.Microbiome · 2023Article
- Review
- Antagonistic activity of selenium-enriched Bifidobacterium breve against Clostridioides difficile.Applied microbiology and biotechnology · 2022Article
- Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model.Microbiology spectrum · 2022Article
- Gut Microbiota Diversity of Preterm Neonates Is Associated WithFrontiers in cellular and infection microbiology · 2022Article
- Evaluation of the therapeutic effect and dose-effect of Bifidobacterium breve on the primary Clostridioides difficile infected mice.Applied microbiology and biotechnology · 2021Article
- Synergy between "Probiotic" Carbon Quantum Dots and Ciprofloxacin in Eradicating Infectious Biofilms and Their Biosafety in Mice.Pharmaceutics · 2021Article
- 2'FL and LNnT Exert Antipathogenic Effects againstPathogens (Basel, Switzerland) · 2021Article
- The Human Gut MicrobeAntibiotics (Basel, Switzerland) · 2021Article
- Gut Dysbiosis andFrontiers in microbiology · 2021Review
- Using Probiotics as Supplementation forInternational journal of molecular sciences · 2020Review
- Transcriptome Analysis of theFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.